BioLife Solutions, Inc.

This is our final post of our week-long dive into ‘Biopreservation Best Practices’ shared from Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer. These snippets were taken from Dr. Mathew’s talk at the BioProcess International West Conference earlier this year.

🚨 An important question is posed in this portion of the presentation:

Do you understand the difference between perceived viability (yield) vs. true viable recovery?

⌛ Dr. Mathew discusses the concepts of Delayed Onset Cell Death (DOCD), apoptosis, necrosis, and other long-term issues that could show up later, 24 – 72 hours after thawing cells, not immediately or a few hours post-thaw.

✅ Running multiple assays, tiers, and time frames will help you to fully understand, characterize, and validate your cell product.

Check out the data in the video. 🔎

In today’s post Dr. Aby J. Mathew explores a cell’s experience during biopreservation processes (freezing and thawing), that causes stress and other negative effects – such as slow or dysfunctional membrane pumps and ice crystal growth. ❄️

While presenting at the BioProcess International West Conference in San Diego earlier this year, Dr. Mathew, our Executive Vice President and Chief Scientific Officer, suggested that utilizing an optimized biopreservation media can help mitigate these various stressors and improve cell function. 📈 🎯

🎥 Learn more about ‘Cell Stressors’ in this video clip.

It’s day three of our week-long series exploring key biopreservation best practices that Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, shared during his presentation at the spring BioProcess International West Conference.

💥 In this portion, Dr. Mathew discusses common cellular responses to biopreservation processes that can cause challenges and stress to cells at multiple levels AND at multiple points in your workflow; all of which may impact your cells negatively.

💭 If you’re not seeing desired cell performance and outcomes, then this video clip is a must-see for the cell environment you should consider, such as decreased metabolic activity and the formation of extra- and intra-cellular ice.

Watch now. 👇

As we mentioned on Monday, Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, gave a presentation called “Biopreservation Best Practices for Cell-based Products” at BioProcess International West earlier this year.

Today we’re focusing on how cryopreservation is not just ‘one step’ in cell and gene therapy production.

⚠️ Challenge: Within a cryopreservation process, there are multiple steps and considerations that can greatly affect your outcome including: your choice of media solutions, cell concentrations, temperature, cooling & thawing rates, wash post-thaw or not, and more.

🧩 Solution: Analyze how you can optimize each step within this process. Look at your upstream and downstream processes too, BEFORE you get to the clinical phase and commercialization.

Hear what Dr. Mathew has to say in less than two minutes below. 🎤

Do you have specific cryopreservation questions? Ask us here: https://www.biolifesolutions.com/cell-processing/biopreservation-media/ask-the-scientists

During the Bioprocessing International West Conference earlier this year in San Diego, Dr. Aby J. Mathew, our Executive Vice President and Chief Scientific Officer, gave a presentation called “Biopreservation Best Practices for Cell-based Products”.

This week in five posts, we are highlighting a few key topics from Dr. Mathew’s talk that stress the importance of implementing these best practices.

⚠️ Challenge: Traditional methods in the lab don’t always translate to cell therapy manufacturing or the desired cell efficacy.

🧩 Solution: When assessing your processes, reach out to a partner that can help you optimize and translate your workflows to a GMP-ready manufacturing environment.

🎬 Watch this quick clip to hear Dr. Mathew’s take.